

<https://www.cdc.gov/kidney-disease/media/pdfs/CKD-Factsheet-H.pdf>

<https://www.cdc.gov/kidney-disease/about/index.html>

Trevisan R, Et al. *J Am Soc Nephrol*. 2006;17:S145-7.

Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2019.

Jo W, et al. *PLoS One*. 2020;15:e0238111.

National Kidney Foundation. 2021. Aging and Kidney Disease.

https://www.kidney.org/news/monthly/wkd_aging.

Chisholm-Burns MA, et al. *Pharmacotherapy Principles & Practice Second Edition*. McGraw-Hill; 2010.

Fatehi P, Hsu C. Chronic kidney disease (newly identified): Clinical presentation and diagnostic approach in adults. Last updated: Jul 9, 2024. UpToDate. https://www.uptodate.com/contents/chronic-kidney-disease-newly-identified-clinical-presentation-and-diagnostic-approach-in-adults?search=ckd&source=search_result&selectedTitle=2%7E150&usage_type=default&display_rank=2#H1570309785

How to Manage Your CKD Patients. *National Kidney Foundation*. 2014.

https://www.kidney.org/sites/default/files/How_to_manage_CKD_patients_conf.pdf.

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International Supplements*. 2024;105(4S).

<https://www.ncqa.org/hedis/measures/kidney-health-evaluation-for-patients-with-diabetes/>

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney International Supplements*. 2022;102:S1-127.

Ndumele CE, Rangaswami J, Chow S, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. *Circulation*. 2023;148:1606-35.

Heerspink HJ, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med*. 2020;383:1436-46.

The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med*. 2023;388:117-27.

Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N Engl J Med*. 2019;380:2295-306.

Fernandez-Fernandez B, Sarafidis P, Jose Soler M, Ortiz A. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. *Clinical Kidney Journal*. 2023;0:1-12

Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. *N Engl J Med*. 2024;391:109-21.

Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009 Mar;4(3):542-51. doi: 10.2215/CJN.04750908.

Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991-2002